---
title: "Bayer's adjusted EBITDA for the third quarter rose nearly 21%, beating expectations"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/265462951.md"
description: "German pharmaceutical giant Bayer announced its third-quarter results, with adjusted EBITDA rising 20.8% to €1.51 billion, exceeding market expectations of €1.29 billion. Sales fell 3.1% year-on-year to €9.66 billion, below expectations. CEO Bill Anderson is committed to rebuilding investor trust and has promised to manage legal risks by the end of next year while implementing efficiency improvement plans. Bayer's stock price has risen over 40% this year, but it is still below pre-Monsanto acquisition levels"
datetime: "2025-11-12T07:35:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265462951.md)
  - [en](https://longbridge.com/en/news/265462951.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265462951.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/265462951.md) | [English](https://longbridge.com/en/news/265462951.md)


# Bayer's adjusted EBITDA for the third quarter rose nearly 21%, beating expectations

German pharmaceutical and chemical giant Bayer announced its third-quarter results, with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) rising 20.8% to €1.51 billion, exceeding market expectations of €1.29 billion. Sales fell 3.1% year-on-year to €9.66 billion, which was below expectations; the adjusted EBITDA margin increased by 3 percentage points year-on-year to 15.6%.

CEO Bill Anderson is working to rebuild investor trust in Bayer. The company is facing numerous legal disputes in the U.S. due to its herbicide "Roundup" and other chemical products inherited from its acquisition of Monsanto in 2018. Anderson has pledged to significantly control legal risks by the end of next year while implementing an efficiency improvement plan that has already cut thousands of jobs.

Bayer's stock price has risen over 40% this year to date, with analysts betting on a business turnaround, but the stock price remains well below levels prior to the Monsanto deal

### 相關股票

- [Bayer Aktiengesellschaft (BAYZF.US)](https://longbridge.com/zh-HK/quote/BAYZF.US.md)

## 相關資訊與研究

- [<![CDATA[Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock]]>](https://longbridge.com/zh-HK/news/280356353.md)
- [Bayer - AskBio announces completion of enrollment in phase 2 clinical trial of AB-1002](https://longbridge.com/zh-HK/news/281314240.md)
- [Bayer Crop Science Canada Redefines Canola Innovation With New "Advancing Better Canola" Initiative | BAYRY Stock News](https://longbridge.com/zh-HK/news/280658062.md)
- [Jeff Ubben's Inclusive Capital Sells $369 Million in Bayer Stock](https://longbridge.com/zh-HK/news/280318062.md)
- [Bayer Secures Regulatory Nod for MRI Contrast Agent in Japan](https://longbridge.com/zh-HK/news/280112038.md)